Is HM6A undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6
Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of HM6A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: HM6A (€3.26) is trading below our estimate of fair value (€10)
Significantly Below Fair Value: HM6A is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HM6A?
Key metric: As HM6A is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for HM6A. This is calculated by dividing HM6A's market cap by their current
earnings.
What is HM6A's PE Ratio?
PE Ratio
8.2x
Earnings
R$1.57b
Market Cap
R$12.82b
HM6A key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Earnings vs Industry: HM6A is good value based on its Price-To-Earnings Ratio (8.2x) compared to the European Pharmaceuticals industry average (20.1x).
Price to Earnings Ratio vs Fair Ratio
What is HM6A's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
HM6A PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
8.2x
Fair PE Ratio
16.2x
Price-To-Earnings vs Fair Ratio: HM6A is good value based on its Price-To-Earnings Ratio (8.2x) compared to the estimated Fair Price-To-Earnings Ratio (16.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.